Cargando…

Individualised treatment targets in patients with type-2 diabetes and hypertension

AIM: Patients with type-2 diabetes mellitus (T2DM) are at high risk of cardiovascular events, accentuated in the presence of hypertension. At present, it is unclear to what extent the guidelines for the management of T2DM, advocating reduction in HbA1c levels to below target levels, are being adhere...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmieder, Roland E., Tschöpe, Diethelm, Koch, Cornelia, Ouarrak, Taoufik, Gitt, Anselm K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778654/ https://www.ncbi.nlm.nih.gov/pubmed/29357854 http://dx.doi.org/10.1186/s12933-018-0661-8

Ejemplares similares

Achievement of individualized treatment targets in patients with comorbid type-2 diabetes and hypertension: 6 months results of the DIALOGUE registry
por: Schmieder, Roland E, et al.
Publicado: (2015)

Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice – study rationale and protocol of DIALOGUE
por: Gitt, Anselm K, et al.
Publicado: (2012)

Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia
por: Bramlage, Peter, et al.
Publicado: (2012)

A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy
por: Gitt, Anselm K, et al.
Publicado: (2015)

Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients - an analysis of the DiaRegis registry
por: Tschöpe, Diethelm, et al.
Publicado: (2011)

Co-morbidity but not dysglycaemia reduces quality of life in patients with type-2 diabetes treated with oral mono- or dual combination therapy – an analysis of the DiaRegis registry
por: Wasem, Jürgen, et al.
Publicado: (2013)

Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-up
por: Bramlage, Peter, et al.
Publicado: (2014)

Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry
por: Gitt, Anselm K., et al.
Publicado: (2016)

Incidence and predictors of hypoglycaemia in type 2 diabetes – an analysis of the prospective DiaRegis registry
por: Tschöpe, Diethelm, et al.
Publicado: (2012)

The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry
por: Bramlage, Peter, et al.
Publicado: (2015)

Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) - study protocol and patient characteristics at baseline
por: Bramlage, Peter, et al.
Publicado: (2010)

The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes
por: Tschöpe, Diethelm, et al.
Publicado: (2013)

EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy – rationale and design of the EARLY hypertension registry
por: Gitt, Anselm K, et al.
Publicado: (2013)

Early vascular parameters in the micro- and macrocirculation in type 2 diabetes
por: Kannenkeril, Dennis, et al.
Publicado: (2018)

Analysis of an Individualised Stepwise Approach to Non-Pharmacological Therapy in COVID-19
por: Matthes, Sandhya, et al.
Publicado: (2023)

Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes
por: Ott, Christian, et al.
Publicado: (2014)

How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial
por: Bosch, Agnes, et al.
Publicado: (2019)

Clinical Inertia in Individualising Care for Diabetes: Is There Time to do More in Type 2 Diabetes?
por: Strain, William David, et al.
Publicado: (2014)

Hypertension and Diabetes: What are the pros to treating early surrogates?
por: Schmieder, Roland E.
Publicado: (2009)

Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update
por: Hanefeld, Markolf, et al.
Publicado: (2020)

Midlife development of type 2 diabetes and hypertension in women by history of hypertensive disorders of pregnancy
por: Timpka, Simon, et al.
Publicado: (2018)

Towards individualisation of treatment in endometrial cancer
por: Taylor, S E, et al.
Publicado: (2012)

Target organ damage and cardiovascular complications in patients with hypertension and type 2 diabetes in Spain: a cross-sectional study
por: Cea-Calvo, Luis, et al.
Publicado: (2006)

Nocturnal blood pressure fall as predictor of diabetic nephropathy in hypertensive patients with type 2 diabetes
por: Felício, João S, et al.
Publicado: (2010)

Vascular Effects of Dietary Advanced Glycation End Products
por: Stirban, Alin, et al.
Publicado: (2015)

Individualised prescription of medications for treatment of obesity in adults
por: Hocking, Samantha, et al.
Publicado: (2023)

Individualising treatment choices in a crowded treatment algorithm
por: Fisher, Rosalie, et al.
Publicado: (2013)

Proteasome Modulator 9 SNPs are linked to hypertension in type 2 diabetes families
por: Gragnoli, Claudia
Publicado: (2011)

Determinants of uncontrolled hypertension in adult type 2 diabetes mellitus: an analysis of the Malaysian diabetes registry 2009
por: Chew, Boon How, et al.
Publicado: (2012)

Increased prevalence of left ventricular hypertrophy in hypertensive women with type 2 diabetes mellitus
por: Tenenbaum, Alexander, et al.
Publicado: (2003)

Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers
por: Gessner, Arne, et al.
Publicado: (2022)

Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies
por: Schernthaner, Guntram, et al.
Publicado: (2018)

The management of acute venous thromboembolism in clinical practice – study rationale and protocol of the European PREFER in VTE Registry
por: Agnelli, Giancarlo, et al.
Publicado: (2015)

Vascular miR-181b controls tissue factor-dependent thrombogenicity and inflammation in type 2 diabetes
por: Witkowski, Marco, et al.
Publicado: (2020)

Gynaecomastia Surgery: Should it be Individualised?
por: Ghnnam, Wagih Mommataz
Publicado: (2014)

Towards Multidimensional Radiotherapy: Key Challenges for Treatment Individualisation
por: Toma-Dasu, Iuliana, et al.
Publicado: (2015)

Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study
por: Liu, Chi-Hung, et al.
Publicado: (2020)

Relationship of autonomic imbalance and circadian disruption with obesity and type 2 diabetes in resistant hypertensive patients
por: Boer-Martins, Leandro, et al.
Publicado: (2011)

Diastolic orthostatic hypertension and cardiovascular prognosis in type 2 diabetes: a prospective cohort study
por: Wijkman, Magnus, et al.
Publicado: (2016)

Prevalence of Hypertension and Albuminuria in Pediatric Type 2 Diabetes: A Systematic Review and Meta-analysis
por: Cioana, Milena, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ur8i3u5cnvku0qhb4epaq7ikfk